LGT Capital Partners’s Haemonetics HAE Stock Holding History

LGT Capital Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-111,898	Closed	-$10M	–	66
2023 Q3	$10M	Hold	111,898	–	–	0.36%	44
2023 Q2	$9.53M	Sell	111,898 -80,561	-42%	-$6.81M	0.33%	45
2023 Q1	$15.9M	Sell	192,459 -105,020	-35%	-$8.5M	0.44%	38
2022 Q4	$23.4M	Sell	297,479 -473,510	-61%	-$38.1M	0.68%	35
2022 Q3	$57.1M	Sell	770,989 -217,160	-22%	-$15.6M	1.74%	21
2022 Q2	$64.4M	Buy	988,149 +21,650	+2%	+$1.28M	1.96%	19
2022 Q1	$61.1M	Sell	966,499 -249,560	-21%	-$13.6M	1.74%	25
2021 Q4	$64.5M	Buy	1,216,059 +36,400	+3%	+$2.22M	1.72%	25
2021 Q3	$83.3M	Buy	1,179,659 +226,234	+24%	+$14.3M	2.51%	17
2021 Q2	$63.5M	Buy	+953,425	New	+$67.5M	1.8%	20

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LGT Capital Partners's HAE Position: Q4 2023 in Review

LGT Capital Partners sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 111,898 shares — an estimated $10M sold.

LGT Capital Partners first reported a position in HAE in Q2 2021 and held it in 10 quarters. The position peaked at $83.3M in Q3 2021. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

LGT Capital Partners reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
LGT Capital Partners sold 111,898 Haemonetics shares in Q4 2023, an estimated $10M.
LGT Capital Partners first reported a position in Haemonetics in Q2 2021 and held it in 10 quarters.
LGT Capital Partners's Haemonetics position peaked at $83.3M in Q3 2021.
295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on LGT Capital Partners's 13F filing for Q4 2023, filed 18 Jan 2024.